Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06216535 · ClinicalTrials.gov registry record · Phase 2

Escitalopram in Asthma Patients With Frequent Exacerbation

A Phase 2 study of Asthma, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
Phase 2
Development phase
105
Enrollment target
1
Study location

NCT06216535: Recruiting Phase 2 study of Asthma, sponsored by University of Texas Southwestern Medical Center.

NCT06216535 is a Phase 2 study of Asthma that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 105 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06216535, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
105 participants
Enrollment target
1
Study location

Study Summary

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed people with asthma were associated with decreased asthma exacerbations and improvement in asthma control. In this study, the number of asthma exacerbations will be assessed as the primary outcome measure in patients using escitalopram vs. placebo.

Primary Outcome

A count outcome variable capturing the total number of severe asthma exacerbations. Severe asthma exacerbations will be defined by the use of oral corticosteroids ≥ 3 days, or hospitalization or emergency department visit leading to treatment with systemic glucocorticoids

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Escitalopram

Study Locations (1)

Texas

  • UT Southwestern, 1440 Empire Central, Ste. LD4.100 - Dallas

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2025-05-19
Est. Completion 2029-06-01
Phase Phase 2

What NCT06216535 shows while recruiting

NCT06216535 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06216535 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06216535 about?

NCT06216535 is a clinical study titled "Escitalopram in Asthma Patients With Frequent Exacerbation". Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed...

What is the current status of trial NCT06216535?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2025-05-19. Estimated completion is 2029-06-01.

What conditions does trial NCT06216535 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT06216535?

The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).

Who is sponsoring clinical trial NCT06216535?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06216535 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06216535's enrollment target sits among peer trials

105 209th of 374 higher than 165 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06216535, the US trial registry maintained by the National Library of Medicine. NCT06216535 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.